DoseMe Adds Cefepime to Its Model-informed Precision Dosing Platform

December 3, 2023

HITRUST CSF certified Bayesian dosing platformstandardizes dosing mechanisms to optimize antibiotic efficacy in critically ill patients



Jupiter, FL – December 4, 2023 - DoseMe, a leading provider of precision dosing software for therapeutic drug monitoring (TDM) and creators of DoseMeRx and DoseMe Analytics, today announced the availability of its Cefepime model. This model will offer pharmacokinetics and target attainment analyses to identify a rational empirical dosing strategy for Cefepime in critically ill patients, including those with unstable renal function, a common challenge faced by clinicians taking care of these complex patients.  


Mark Scheetz is a professor at Midwestern University, Chicago College of Pharmacy and holds a joint appointment at Department of Pharmacology, College of Graduate Studies and is the Director of Pharmacometric Center of Excellence at Midwestern University. His research continues to highlight three keys to infectious disease monitoring - real time beta lactam monitoring, therapeutic drug monitoring and precision dosing. “Similar to many beta lactam treatments, Cefepime displays a large amount of variability between patients and having DoseMeRx enables precision dosing” stated Scheetz. “Pharmacists know when patients' clearances are changing and they know that creatinine clearance does not capture the drug clearance.  It is going to become more prevalent that all drugs need to be monitored.”  


The fourth-generation cephalosporin antibiotic is used in the treatment and management of gram-positive and gram-negative bacterial infections. Its most common uses are for pneumonia, skin and soft-tissue infections, complicated intra-abdominal infections, and neutropenic fever. Cefepime is associate with a higher risk of neurotoxicity, particularly in renal dysfunction, as evidenced by a study by Boschung-Pasquier, L. et al.  where neurotoxic symptoms were observed in 54% of patients with eGFR<30 mL/min/1.73m2 versus 4% with normal renal function (eGFR > 90 mL/min/1.73m2). Utilizing model-informed precision dosing (MIPD) software could minimize this risk.


“As the awareness around suboptimal dosing as a major factor in patient risk increases,  DoseMe is at the forefront of innovation”, stated Dr. Sharmeen Roy, PharmD, BCPS, Chief Strategy and Science Officer. “The platform combines smart technology with science leveraging clinically-validated PK/PD models and now pharmacists at healthcare organizations around the globe can dose Cefepime with confidence.”


Therapeutic drug monitoring (TDM) and model-informed precision dosing (MIPD) have evolved as important tools to inform rational dosing of antibiotics in individual patients with infections. In particular, critically ill patients are at the highest risk and often suffer from infections caused by less susceptible bacteria.  Greater recognition of the benefits of Model-informed Precision Dosing (MIPD) software for enhancing TDM and dosing precision necessitates thorough validation of models and reassessment of current workflows.


The DoseMe Bayesian approach developed in the study accurately predicts Cefepime concentrations in serum and allows for the estimation of individualized Cefepime pharmacokinetic parameters, minimizing the risk of bias in the prediction. This was demonstrated in patients with both stable and unstable renal function.


For more information and an overview of all models currently available, visit


About DoseMe

DoseMe combines smart technology with science, leveraging clinically-validated PK/PD models, patient characteristics, drug concentrations, and genotype to accurately individualize a dose in seconds. The platform is HIPAA, ISO & FDA compliant and the only Bayesian dosing platform to be HITRUST CSF certified. For more information on successful applications of its products, DoseMeRx and DoseMe Analytics, visit